Frontage Expands Drug Metabolism & Pharmacokinetic (DMPK) Services by Acquiring Biotranex
Exton, Pennsylvania, 01 April, 2020 – Frontage Holdings Corporation ( “Frontage” or the “Group”, 1521.HK), a contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services with presence in both North America and China, today announced Frontage Laboratories, Inc.("Frontage Labs"), a wholly-owned subsidiary of the Group, entered into an equity purchase agreement with third party individuals. According to the agreement, Frontage Labs will purchase the entire equity interest in Biotranex, LLC (“Biotranex”) owned by the individual third parties.